Biotech Stocks Upcoming 3Q Catalyst.


16-Jul-2018 16:29 PM



   Biotech stocks clinical data has more failed results compared to success data results. But you do throughout due diligence and use all the tool guide out there to help with risk mitigation then the risk vs reward will be on your side. Our tool guide is Biotech Calculator with 80% accuracy in predicting clinical data.

    On June 28, 2018, Zogenix, Inc (ZGNX) closed price at $43.25 before Phase 3 clinical data were out.  We shared how to use the #BiotechCalculator from a requested follower as follow info:

"Per request,

ZGNX speculation upcoming data:

Symbol: ZGNX

Phase: 3

Disease Area: Dravet syndrome (Neurology)

Market Cap: $1 billion -above

sign up and try with 83% accuracy"


exactly two weeks later on July 12, 2018.  Zogenix, Inc (ZGNX) press release, "Positive Top-line results from second pivotal  Phase 3 clinical trial of ZX008 in Dravet Syndrome.

the stock moved up +20.30% for the day. As of last closing price July 13, at $61.35 or up 30% since we share the #BiotechCalculator prediction.

    The #BiotechCalculator is powered by a unique mathematical formula that we created and track over many years. It has over 80% accuracy predict biotech clinical data. This is a tool to use to help the biotech investors risk mitigation.  Be open-minded with the #BiotechCalculator, but it's a must-have in your biotech due diligence. Here are more details how we came up with the unique formula

For 3Q biotech upcoming clinical data, our team has gathered most of Phase II and III clinical data for investors to watch and use our#BiotechCalculator. Here are five notable one to watch.

  1. Alnylam Pharmaceuticals. Inc

Symbol: ALNY

Phase: 3

Disease Area: Acute Hepatic Porphyrias (Endocrine)

Market Cap: $1 billion-above

Speculation result


      2. Amarin Corporation plc

Symbol: AMRN

Phase: 3

Disease Area: Cardiovascular

Market Cap: $300 million- $999 million

Speculation result


     3.  BeyondSpring Inc

Symbol: BYSI

Phase: 3

Disease Area: Non-small-cell lung carcinoma (NSCLC) (Oncology)

Market Cap: $300 million- $999 million

Speculation result


      4 Omeros Corporation

Symbol: OMER

Phase: 2

Disease Area: Hematology

Market Cap: $1 billion-above

Speculation result


      5.  TG Therapeutics, Inc 

Symbol: TGTX

Phase: 3

Disease Area: Oncology

Market Cap: $300 million- $999 million

Speculation result

These are speculation results only based on our unique statistics mathematic formula and to be used as a tool guide. Your due diligence is an important role when it comes to investing. Always know what you own.

The biotech upcoming catalyst

Macro events, and FDA PDUFA calendar

Disclaimer: We hold no position in the stocks mentioned above. These are ideas and opinion only and should not be taken as investment advice. Always do your own due diligence and seek the financial adviser for your investment. We hold no insider information. 

Contact us: 

Twitter: @BiotechMoney18




Add Your Comment

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.